Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Trial Profile

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2019

At a glance

  • Drugs Neratinib (Primary) ; Fulvestrant; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MutHER
  • Most Recent Events

    • 02 May 2019 Planned number of patients changed from 77 to 80.
    • 02 May 2019 Planned End Date changed from 31 Dec 2021 to 31 May 2024.
    • 02 May 2019 Planned primary completion date changed from 30 Jun 2020 to 30 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top